Sharp Therapeutics Corp. (TSXV:SHRX)

Sharp Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	0.97	0.51	0.55
Research & Development	1.89	1.73	1.79
Operating Expenses	2.88	2.27	2.42
Operating Income	-2.88	-2.27	-2.42
Interest Expense	-0.17	-0.17	-0.18
Other Non Operating Income (Expenses)	-0.79	-0.58	-0.64
EBT Excluding Unusual Items	-3.84	-3.02	-3.23
Gain (Loss) on Sale of Investments	-0.01	-0.01	-0.01
Other Unusual Items	-1.07	-0.54	-0.64
Pretax Income	-4.91	-3.56	-3.88
Net Income	-4.91	-3.56	-3.88
Net Income to Common	-4.91	-3.56	-3.88
Shares Outstanding (Basic)	0	0	0
Shares Outstanding (Diluted)	0	0	0
Shares Change (YoY)	-	0.21%	-
EPS (Basic)	-35.29	-25.62	-27.97
EPS (Diluted)	-35.29	-25.62	-27.97
Free Cash Flow	-2.19	-1.97	-2.05
Free Cash Flow Per Share	-15.76	-14.17	-14.77
EBITDA	-2.9	-2.24	-2.37
D&A For EBITDA	-0.02	0.03	0.05
EBIT	-2.88	-2.27	-2.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.